Basel, Switzerland-based Basilea Pharmaceutica AG appointed Gerrit Hauck as its chief technology officer.
Hauck, who also joins the company's management committee, succeeds Günter Ditzinger, who will take on new responsibilities at Basilea.
Hauck previously worked at Sanofi where he was overseeing most of the company's technical development programs for synthetic molecules.
At the same time, he was a member of Sanofi's research stage gate committee, which is responsible for the transition of candidate molecules from research into development.
Additionally, Josef Künzle, head of Basilea's global quality management and a member of the extended management committee, will retire Oct. 31.
Basilea named Anne Stehlin as Künzle's successor, who joins the company from Novartis AG where she served as global head of product quality lifecycle management.
Stehlin will initially serve as Basilea's deputy head of global quality management until Oct. 31.
Basilea Pharmaceutica is focusing on the discovery, development and commercialization of products in the areas of bacterial and fungal infections and oncology.